BUZZ-Biohaven climbs as FDA says no advisory committee needed for genetic disorder drug
I'm PortAI, I can summarize articles.
Biohaven's shares rose 9.2% to $16.03 premarket after the FDA announced that an advisory committee meeting for its genetic disorder drug, troriluzole, is no longer necessary. The FDA had previously extended the review period for the drug, which is being tested for spinocerebellar ataxia, a rare disorder with no approved treatments. The decision is expected in Q4 of 2025, despite the stock being down 60% year-to-date.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments